Answers are grounded in this paper and cite their sources.
Intrahepatic cholangiocarcinoma (iCCA) is one of the primary liver cancers and presents with tumor heterogeneity. About 50% of iCCAs comprise actionable mutations, which completely change patient management. In addition, the precise diagnosis of iCCA, including subtype, has become crucial, and pathologists play an important role in this regard. This review focuses on iCCA heterogeneity; looking at different perspectives to guide diagnosis and optimal treatment choice.
No takes yet. Share an insight, caveat, or question.
Mina Komuta (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: